Key result
Elevated LV mass index linked to ~15% higher mortality risk across standard clinical cutoffs.
Why the study?
Although myocardial mass reflects a continuous structural adaptation to chronic hemodynamic load, increased left ventricular mass is typically classified categorically as hypertrophy, motivating an examination of the continuous association of left ventricular mass index with mortality and cardiovascular outcomes in a general population.
Is continuous left ventricular mass index (LVMI) associated with all-cause mortality and incident cardiovascular outcomes in a general adult population?
Cohort (n=12,046)
No
Is continuous left ventricular mass index (LVMI) associated with all-cause mortality and incident cardiovascular outcomes in a general adult population?
Left ventricular mass index (LVMI) demonstrates a continuous linear relationship with mortality and incident cardiovascular disease in the general population, with elevated risk present even below conventional hypertrophy thresholds.
Continuous LVMI-mortality link below hypertrophy cutoffs may refine risk models; leaves open whether reduction improves outcomes.
Introduction Myocardial mass mostly reflects a continuous structural adaptation to chronic hemodynamic load. Increased left ventricular mass is categorically classified as left ventricular hypertrophy being associated with higher risk of mortality. Purpose We aimed to characterize the distinct distribution of left ventricular mass index (LVMI) and to examine its continuous association with mortality and cardiovascular outcomes in a general population. Methods We analysed transthoracic echocardiography data from the prospective Hamburg City Health Study, a population-based cohort of adults aged 45–74 years between 2016 to 2021 with a median follow up of 4.8 (IQR 3.0-5.9) years. LVMI was calculated as: LVMI (g/m2) = (0.8 × [1.04 × ((Interventricular Septal Diameter + Left Ventricular End-Diastolic Diameter + Posterior Wall Diameter)3 − (Left Ventricular End-Diastolic Diameter)3)] + 0.6) / Body Surface Area (m2)). The primary outcome was all-cause mortality (ACM) and the secondary outcome a composite of incident cardiovascular disease (heart failure, myocardial infarction, atrial fibrillation, pulmonary embolism, or stroke) and ACM. Associations were assessed with Cox proportional-hazards models using age as the time-scale and adjusted for sex. Continuous variables are presented as medians (interquartile ranges; IQR) unless otherwise specified. Results A total of 12,046 participants with complete echocardiographic data were included; 50.8% were women, the median age was 60 (IQR 14.5) years, and median body mass index was 25.8 (23-28.1) kg/m2. The median LVMI was 79.6 (69–93) g/m2 overall, 73.9 (65–85) g/m2 in women, and 86.6 (75–101) g/m2 in men. LVMI was continuously associated with overall mortality and the composite outcome (Figure 1), with an approximately linear relation and progressively higher risk at increasing LVMI values. The risk of mortality or composite primary outcome was already higher at conventional hypertrophy cut-offs in women (95 g/m2; hazard ratio [HR] 1.15 95% Confidence Interval [CI] 1.09–1.22) and in men (115 g/m2; HR 1.376, 95% CI 1.205–1.571). Conclusion With increasing LVMI, risk of mortality or incident cardiovascular disease increased continuously exceeding with higher values. LVMI values below established cutoffs were already associated with higher risk, supporting consideration of myocardial mass across its full spectrum and suggesting potential value of earlier risk stratification.
No takes yet. Share an insight, caveat, or question.
Senftinger et al. (2026) conducted a cohort in Left ventricular hypertrophy / cardiovascular risk in general population (n=12,046). Left ventricular mass index (LVMI) vs. Lower LVMI values (continuous spectrum) was evaluated on All-cause mortality (ACM) (HR 1.15 (women at 95 g/m2); HR 1.376 (men at 115 g/m2), 95% CI 1.09-1.22 (women); 1.205-1.571 (men)). Left ventricular mass index was continuously associated with higher risk of mortality and cardiovascular disease at cutoffs of 95 g/m2 in women (HR 1.15) and 115 g/m2 in men (HR 1.376).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: